Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-23-014872

EVP, Chief Development Officer acquired 95,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Poulton Stuart EVP, Chief Development Officer 2023-02-28 Grant or award +95,000 159,131 D: show line 1 in the form
Loading xslF345X03/doc4.xml…